{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:32:08Z","timestamp":1792798328747,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Allogeneic haematopoietic cell transplantation (allo-HCT) remains the only potentially curative option for patients with myelofibrosis (MF), yet the integration of JAK inhibitors (JAKi) and novel agents into transplant pathways has created increasing complexity. To capture current real-world practice, the EBMT Chronic Malignancies Working Party conducted a survey of 19 high-volume European centres performing MF allo-HCT. Most centres (68%) routinely initiated JAKi, primarily ruxolitinib, in transplant-eligible patients prior to conditioning, with goals of splenomegaly reduction and symptom control. Management of ruxolitinib intolerance or resistance was heterogeneous, with strategies including switching to alternative JAKi, proceeding directly to allo-HCT, or enroling in clinical trials. Peri-transplant approaches also varied: over half of centres continued ruxolitinib throughout conditioning, while others employed tapering or abrupt discontinuation. Experience with newer JAKi and investigational therapies was limited. Post-transplant, most centres did not routinely reintroduce JAKi, although some used them for relapse or GVHD mitigation. Notably, many centres reported transplant delays due to prolonged medical therapy, with adverse consequences including disease progression. These findings highlight significant heterogeneity in practice, which is likely to increase as more novel agents are integrated in treatment algorithms. Harmonised, multidisciplinary guidelines to optimise timing and outcomes for MF patients eligible for allo-HCT are needed.<\/jats:p>","DOI":"10.1038\/s41409-025-02780-2","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T11:27:52Z","timestamp":1766575672000},"page":"333-340","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on \u2018real world\u2019 experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithm"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2681-5860","authenticated-orcid":false,"given":"Alexandros","family":"Rampotas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Maria","family":"Aspa-Cilleruelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Koster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Avenoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7092-3351","authenticated-orcid":false,"given":"Jakob","family":"Passweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8090-0349","authenticated-orcid":false,"given":"Elisa","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-9876","authenticated-orcid":false,"given":"Marie","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Eivind","family":"Myhre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7470-2994","authenticated-orcid":false,"given":"Moniek","family":"de Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erfan","family":"Nur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3142-5581","authenticated-orcid":false,"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8519-4187","authenticated-orcid":false,"given":"Micha","family":"Srour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1355-1587","authenticated-orcid":false,"given":"Patrizia","family":"Chiusolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urpu","family":"Salmenniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike","family":"Verbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1857-5836","authenticated-orcid":false,"given":"Maria Chiara","family":"Finazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Castilla-Llorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3732-5442","authenticated-orcid":false,"given":"Marie Therese","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9112-5017","authenticated-orcid":false,"given":"Patryk","family":"Sobieralski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Sockel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Alabdulkarim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4562-6264","authenticated-orcid":false,"given":"Joanna","family":"Drozd-Sokolowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8258-354X","authenticated-orcid":false,"given":"Kavita","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0695-3879","authenticated-orcid":false,"given":"Giorgia","family":"Battipaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Czerw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6297-9697","authenticated-orcid":false,"given":"Nicola","family":"Polverelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-3113","authenticated-orcid":false,"given":"Juan Carlos","family":"Hern\u00e1ndez-Boluda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1224-091X","authenticated-orcid":false,"given":"Donal P.","family":"McLornan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"2780_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/bjh.19186","volume":"204","author":"DP McLornan","year":"2024","unstructured":"McLornan DP, Psaila B, Ewing J, Innes A, Arami S, Brady J, et al. The management of myelofibrosis: a British Society for Haematology Guideline. Br J Haematol. 2024;204:136\u201350. https:\/\/doi.org\/10.1111\/bjh.19186.","journal-title":"Br J Haematol"},{"key":"2780_CR2","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","volume":"11","author":"N Kr\u00f6ger","year":"2024","unstructured":"Kr\u00f6ger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, et al. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN International Working Group. Lancet Haematol. 2024;11:e62\u201374. https:\/\/doi.org\/10.1016\/S2352-3026(23)00305-8.","journal-title":"Lancet Haematol"},{"key":"2780_CR3","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1182\/blood.2023022415","volume":"145","author":"L Masarova","year":"2025","unstructured":"Masarova L, Chifotides HT. How I individualize selection of JAK inhibitors for patients with myelofibrosis. Blood. 2025;145:1724\u201337. https:\/\/doi.org\/10.1182\/blood.2023022415.","journal-title":"Blood"},{"key":"2780_CR4","doi-asserted-by":"publisher","first-page":"9592","DOI":"10.1182\/blood-2022-163456","volume":"140","author":"J Mascarenhas","year":"2022","unstructured":"Mascarenhas J, Gerds AT, Kiladjian J-J, D\u00f6hner K, Buckley S, Smith JA, et al. PACIFICA: a randomized, controlled phase 3 study of pacritinib versus physician\u2019s choice in patients with primary or secondary myelofibrosis and severe thrombocytopenia. Blood. 2022;140:9592\u20134. https:\/\/doi.org\/10.1182\/blood-2022-163456.","journal-title":"Blood"},{"key":"2780_CR5","doi-asserted-by":"publisher","unstructured":"Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018. https:\/\/doi.org\/10.1016\/S2352-3026(17)30237-5.","DOI":"10.1016\/S2352-3026(17)30237-5"},{"key":"2780_CR6","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","volume":"35","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Kiladjian J-J, Catalano JV, Devos T, Egyed M, Hellmann A, et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-na\u00efve patients with myelofibrosis. J Clin Oncol J Am Soc Clin Oncol. 2017;35:3844\u201350. https:\/\/doi.org\/10.1200\/JCO.2017.73.4418.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"2780_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","volume":"401","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet. 2023;401:269\u201380. https:\/\/doi.org\/10.1016\/S0140-6736(22)02036-0.","journal-title":"Lancet"},{"key":"2780_CR8","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","volume":"4","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017;4:e225\u201336. https:\/\/doi.org\/10.1016\/S2352-3026(17)30027-3.","journal-title":"Lancet Haematol"},{"key":"2780_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1182\/blood-2020-140771","volume":"136","author":"W Ma","year":"2020","unstructured":"Ma W, Balaian L, Mondala P, He Y, Mason C, Pham J, et al. Imetelstat inhibits telomerase and prevents propagation of ADAR1-activated myeloproliferative neoplasm and leukemia stem cells. Blood. 2020;136:18\u201318. https:\/\/doi.org\/10.1182\/blood-2020-140771.","journal-title":"Blood"},{"key":"2780_CR10","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1182\/blood-2019-130158","volume":"134","author":"CN Harrison","year":"2019","unstructured":"Harrison CN, Garcia JS, Mesa RA, Somervaille TC, Komrokji RS, Pemmaraju N, et al. Results from a phase 2 study of navitoclax in combination with ruxolitinib in patients with primary or secondary myelofibrosis. Blood. 2019;134:671\u2013671. https:\/\/doi.org\/10.1182\/blood-2019-130158.","journal-title":"Blood"},{"key":"2780_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1182\/blood-2020-140901","volume":"136","author":"J Mascarenhas","year":"2020","unstructured":"Mascarenhas J, Harrison C, Luptakova K, Christo J, Wang J, Mertz JA, et al. MANIFEST-2, a global, phase 3, randomized, double-blind, active-control study of CPI-0610 and ruxolitinib Vs. placebo and ruxolitinib in JAK-inhibitor-naive myelofibrosis patients. Blood. 2020;136:43. https:\/\/doi.org\/10.1182\/blood-2020-140901.","journal-title":"Blood"},{"key":"2780_CR12","doi-asserted-by":"publisher","unstructured":"Mascarenhas J, Kremyanskaya M, Patriarca A, Palandri F, Devos T, Passamonti F, et al. MANIFEST: pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-na\u00efve myelofibrosis. J Clin Oncol 2023:JCO.22.01972. https:\/\/doi.org\/10.1200\/JCO.22.01972.","DOI":"10.1200\/JCO.22.01972"},{"key":"2780_CR13","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1182\/blood-2024-204953","volume":"144","author":"A Rampotas","year":"2024","unstructured":"Rampotas A, Wong Z, Gannon I, Benlabiod C, Shen Y, Brierley C, et al. Development of a first-in-class CAR-T therapy against calreticulin-mutant neoplasms and evaluation in the relevant human tissue environment. Blood. 2024;144:871\u2013871. https:\/\/doi.org\/10.1182\/blood-2024-204953.","journal-title":"Blood"},{"key":"2780_CR14","doi-asserted-by":"publisher","first-page":"3147.1","DOI":"10.1182\/blood-2024-193905","volume":"144","author":"JO Mascarenhas","year":"2024","unstructured":"Mascarenhas JO, Borate U, Bose P, Byrd JC, Garcia JS, Grunwald MR, et al. A multicenter, open-label, phase 1 clinical trial of AJ1-11095 administered as oral monotherapy in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have been failed by a type I JAK2 inhibitor (JAK2i). Blood. 2024;144:3147.1\u20133147.1. https:\/\/doi.org\/10.1182\/blood-2024-193905.","journal-title":"Blood"},{"key":"2780_CR15","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/cncr.32664","volume":"126","author":"F Palandri","year":"2020","unstructured":"Palandri F, Breccia M, Bonifacio M, Polverelli N, Elli EM, Benevolo G, et al. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. 2020;126:1243\u201352. https:\/\/doi.org\/10.1002\/cncr.32664.","journal-title":"Cancer"},{"key":"2780_CR16","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1002\/cncr.34722","volume":"129","author":"F Palandri","year":"2023","unstructured":"Palandri F, Breccia M, Mazzoni C, Auteri G, Elli EM, Trawinska MM, et al. Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome. Cancer. 2023;129:1704\u201313. https:\/\/doi.org\/10.1002\/cncr.34722.","journal-title":"Cancer"},{"key":"2780_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00392-1","volume":"11","author":"F Palandri","year":"2021","unstructured":"Palandri F, Palumbo GA, Elli EM, Polverelli N, Benevolo G, Martino B, et al. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. Blood Cancer J. 2021;11:4. https:\/\/doi.org\/10.1038\/s41408-020-00392-1.","journal-title":"Blood Cancer J"},{"key":"2780_CR18","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/j.bbmt.2019.06.034","volume":"25","author":"D McLornan","year":"2019","unstructured":"McLornan D, Szydlo R, Koster L, Chalandon Y, Robin M, Wolschke C, et al. Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2019;25:2167\u201371. https:\/\/doi.org\/10.1016\/j.bbmt.2019.06.034.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2780_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jtct.2022.01.018","volume":"28","author":"C Cipkar","year":"2022","unstructured":"Cipkar C, Kumar S, Thavorn K, Kekre N. Optimal timing of allogeneic stem cell transplantation for primary myelofibrosis. Transpl Cell Ther Publ Am Soc Transpl Cell Ther. 2022;28:189\u201394. https:\/\/doi.org\/10.1016\/j.jtct.2022.01.018.","journal-title":"Transpl Cell Ther Publ Am Soc Transpl Cell Ther"},{"key":"2780_CR20","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1038\/s41409-021-01305-x","volume":"56","author":"D McLornan","year":"2021","unstructured":"McLornan D, Eikema DJ, Czerw T, Kr\u00f6ger N, Koster L, Reinhardt HC, et al. Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis. Bone Marrow Transpl. 2021;56:2160\u201372. https:\/\/doi.org\/10.1038\/s41409-021-01305-x.","journal-title":"Bone Marrow Transpl"},{"key":"2780_CR21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/ajh.27529","volume":"100","author":"K Rathje","year":"2025","unstructured":"Rathje K, Gagelmann N, Badbaran A, Langebrake C, Dadkhah A, Richter J, et al. Clinical and immune effects of PERI-transplantation JAK inhibition for myelofibrosis. Am J Hematol. 2025;100:200\u20139. https:\/\/doi.org\/10.1002\/ajh.27529.","journal-title":"Am J Hematol"},{"key":"2780_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00262-025-04046-8","volume":"74","author":"S Villar","year":"2025","unstructured":"Villar S, Curis E, Schlageter M-H, Bosselut N, Charbonnier A, Rubio M-T, et al. Ruxolitinib stopped before transplantation does not induce cytokine release in myelofibrosis. Cancer Immunol Immunother CII. 2025;74:181 https:\/\/doi.org\/10.1007\/s00262-025-04046-8.","journal-title":"Cancer Immunol Immunother CII"},{"key":"2780_CR23","unstructured":"Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis. Bone Marrow Transplant. 2024. https:\/\/www.nature.com\/articles\/s41409-024-02252-z."},{"key":"2780_CR24","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/S2352-3026(22)00330-1","volume":"10","author":"N Polverelli","year":"2023","unstructured":"Polverelli N, Hern\u00e1ndez-Boluda JC, Czerw T, Barbui T, D\u2019Adda M, Deeg HJ, et al. Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol. 2023;10:e59\u201370. https:\/\/doi.org\/10.1016\/S2352-3026(22)00330-1.","journal-title":"Lancet Haematol"},{"key":"2780_CR25","doi-asserted-by":"publisher","unstructured":"Kr\u00f6ger N, Sbianchi G, Sirait T, Wolschke C, Beelen D, Passweg J, et al. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. Leukemia 2021. https:\/\/doi.org\/10.1038\/s41375-021-01276-4.","DOI":"10.1038\/s41375-021-01276-4"},{"key":"2780_CR26","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1182\/bloodadvances.2021005035","volume":"6","author":"H Ali","year":"2022","unstructured":"Ali H, Tsai N-C, Synold T, Mokhtari S, Tsia W, Palmer J, et al. Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study. Blood Adv. 2022;6:1444\u201353. https:\/\/doi.org\/10.1182\/bloodadvances.2021005035.","journal-title":"Blood Adv"},{"key":"2780_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.760789","volume":"11","author":"KJ Snyder","year":"2021","unstructured":"Snyder KJ, Choe HK, Gao Y, Sell NE, Braunreiter KM, Zitzer NC, et al. Inhibition of Bromodomain and Extra Terminal (BET) domain activity modulates the IL-23R\/IL-17 axis and suppresses acute graft-versus-host disease. Front Oncol. 2021;11:760789. https:\/\/doi.org\/10.3389\/fonc.2021.760789.","journal-title":"Front Oncol"},{"key":"2780_CR28","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.jid.2020.02.029","volume":"140","author":"J Strobl","year":"2020","unstructured":"Strobl J, Pandey RV, Krausgruber T, Kleissl L, Reininger B, Herac M, et al. Anti-apoptotic molecule BCL2 is a therapeutic target in steroid-refractory graft-versus-host disease. J Invest Dermatol. 2020;140:2188\u201398. https:\/\/doi.org\/10.1016\/j.jid.2020.02.029.","journal-title":"J Invest Dermatol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02780-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02780-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02780-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:56:06Z","timestamp":1772808966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02780-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2780"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02780-2","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study involved an anonymised survey of clinicians. No personal or patient data were collected, and therefore formal ethics approval was not required","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent of participate"}}]}}